File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s00296-020-04583-8
- Scopus: eid_2-s2.0-85084081744
- PMID: 32318800
- WOS: WOS:000528118500002
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis
Title | A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis |
---|---|
Authors | |
Keywords | Arthritis Rheumatoid Tuberculosis Risk factors Antirheumatic agents |
Issue Date | 2020 |
Publisher | Springer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00296/index.htm |
Citation | Rheumatology International: clinical and experimental investigations, 2020, v. 40, p. 983-990 How to Cite? |
Abstract | Tuberculosis (TB) is an important preventable infection in patients with rheumatoid arthritis (RA). To determine the risk of TB in patients with RA by comparing with those with non-specific back pain (NSBP), and to identify the risk factors in the RA group. Medical data were retrieved from a centralized electronic database. A total of 1099 patients with RA and 2489 patients with NSBP were identified. Clinical data, comorbidities, and use of individual disease-modifying anti-rheumatic drugs (DMARDs) were retrieved. Risks of TB in patients with RA and NSBP were compared by propensity score (PS) adjusted analysis with known or potential risk factors for TB. Risk factors of TB were also determined in patients with RA. There were 14 cases of TB in RA group and 25 cases in NSBP group. Median duration of follow-up were 11.3 (0.1–21.9) years in RA group and 15.4 (0.1–24.4) years in NSBP group. The risk of TB in patients with RA was 2.53 times higher (HR 2.53; 95% CI 1.29, 4.94; p < 0.01) than in patients with NSBP. After excluding patients on DMARDs, the risk became similar (HR 2.72; 95% CI 0.81, 9.14; p = 0.11). Independent risk factors found were etanercept (HR 7.16; 95% CI 1.41, 36.30; p = 0.02), and previous TB infection (HR 25.23; 95% CI 6.99, 91.09; p < 0.001). The risk of extrapulmonary involvement between RA and NSBP groups was similar (HR 1.21; 95% CI 0.22, 6.57; p = 0.83). The risk of TB was increased in patients with RA. Anti-TNF therapy was an identified risk factor. |
Persistent Identifier | http://hdl.handle.net/10722/282233 |
ISSN | 2023 Impact Factor: 3.2 2023 SCImago Journal Rankings: 0.971 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, TT | - |
dc.contributor.author | Ko, HJ | - |
dc.contributor.author | Lau, CS | - |
dc.contributor.author | Chung, HY | - |
dc.date.accessioned | 2020-05-05T14:32:31Z | - |
dc.date.available | 2020-05-05T14:32:31Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Rheumatology International: clinical and experimental investigations, 2020, v. 40, p. 983-990 | - |
dc.identifier.issn | 0172-8172 | - |
dc.identifier.uri | http://hdl.handle.net/10722/282233 | - |
dc.description.abstract | Tuberculosis (TB) is an important preventable infection in patients with rheumatoid arthritis (RA). To determine the risk of TB in patients with RA by comparing with those with non-specific back pain (NSBP), and to identify the risk factors in the RA group. Medical data were retrieved from a centralized electronic database. A total of 1099 patients with RA and 2489 patients with NSBP were identified. Clinical data, comorbidities, and use of individual disease-modifying anti-rheumatic drugs (DMARDs) were retrieved. Risks of TB in patients with RA and NSBP were compared by propensity score (PS) adjusted analysis with known or potential risk factors for TB. Risk factors of TB were also determined in patients with RA. There were 14 cases of TB in RA group and 25 cases in NSBP group. Median duration of follow-up were 11.3 (0.1–21.9) years in RA group and 15.4 (0.1–24.4) years in NSBP group. The risk of TB in patients with RA was 2.53 times higher (HR 2.53; 95% CI 1.29, 4.94; p < 0.01) than in patients with NSBP. After excluding patients on DMARDs, the risk became similar (HR 2.72; 95% CI 0.81, 9.14; p = 0.11). Independent risk factors found were etanercept (HR 7.16; 95% CI 1.41, 36.30; p = 0.02), and previous TB infection (HR 25.23; 95% CI 6.99, 91.09; p < 0.001). The risk of extrapulmonary involvement between RA and NSBP groups was similar (HR 1.21; 95% CI 0.22, 6.57; p = 0.83). The risk of TB was increased in patients with RA. Anti-TNF therapy was an identified risk factor. | - |
dc.language | eng | - |
dc.publisher | Springer Verlag. The Journal's web site is located at http://link.springer.de/link/service/journals/00296/index.htm | - |
dc.relation.ispartof | Rheumatology International: clinical and experimental investigations | - |
dc.rights | This is a post-peer-review, pre-copyedit version of an article published in [insert journal title]. The final authenticated version is available online at: http://dx.doi.org/[insert DOI] | - |
dc.subject | Arthritis | - |
dc.subject | Rheumatoid | - |
dc.subject | Tuberculosis | - |
dc.subject | Risk factors | - |
dc.subject | Antirheumatic agents | - |
dc.title | A retrospective study on the risk of tuberculosis in patients with rheumatoid arthritis | - |
dc.type | Article | - |
dc.identifier.email | Lau, CS: cslau@hku.hk | - |
dc.identifier.email | Chung, HY: jameschy@hku.hk | - |
dc.identifier.authority | Lau, CS=rp01348 | - |
dc.identifier.authority | Chung, HY=rp02330 | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s00296-020-04583-8 | - |
dc.identifier.pmid | 32318800 | - |
dc.identifier.scopus | eid_2-s2.0-85084081744 | - |
dc.identifier.hkuros | 309832 | - |
dc.identifier.volume | 40 | - |
dc.identifier.spage | 983 | - |
dc.identifier.epage | 990 | - |
dc.identifier.isi | WOS:000528118500002 | - |
dc.publisher.place | Germany | - |
dc.identifier.issnl | 0172-8172 | - |